These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7997379)

  • 1. Superselective radioembolization of hepatocellular carcinoma: 5-year results of a prospective study.
    Rösler H; Triller J; Baer HU; Geiger L; Beer HF; Becker C; Blumgart LH
    Nuklearmedizin; 1994 Oct; 33(5):206-14. PubMed ID: 7997379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with
    Hermann AL; Dieudonné A; Ronot M; Sanchez M; Pereira H; Chatellier G; Garin E; Castera L; Lebtahi R; Vilgrain V;
    Radiology; 2020 Sep; 296(3):673-684. PubMed ID: 32602828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases.
    Kousik V; Promila P; Verma R; Gupta A
    Indian J Gastroenterol; 2016 May; 35(3):179-85. PubMed ID: 27185180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison.
    Gnesin S; Canetti L; Adib S; Cherbuin N; Silva Monteiro M; Bize P; Denys A; Prior JO; Baechler S; Boubaker A
    J Nucl Med; 2016 Nov; 57(11):1672-1678. PubMed ID: 27307346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Methods for the superselective radioembolization of liver tumors with 90yttrium-resin particles].
    Triller J; Rösler H; Geiger L; Baer HU
    Rofo; 1994 Nov; 161(5):425-31. PubMed ID: 7948997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity.
    Padia SA; Kwan SW; Roudsari B; Monsky WL; Coveler A; Harris WP
    J Vasc Interv Radiol; 2014 Jul; 25(7):1067-73. PubMed ID: 24837982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
    Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
    Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma.
    Iñarrairaegui M; Martinez-Cuesta A; Rodríguez M; Bilbao JI; Arbizu J; Benito A; Alegre F; D'Avola D; Herrero JI; Quiroga J; Prieto J; Sangro B
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1441-8. PubMed ID: 20056355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECT.
    Lam MG; Goris ML; Iagaru AH; Mittra ES; Louie JD; Sze DY
    J Nucl Med; 2013 Dec; 54(12):2055-61. PubMed ID: 24144563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Miscalculated Lung Shunt Fraction for Planning of Hepatic Radioembolization.
    Caskey JS; Kay MD; McMillan NA; Kuo PH; Woodhead GJ
    J Nucl Med Technol; 2020 Jun; 48(2):184-186. PubMed ID: 31811062
    [No Abstract]   [Full Text] [Related]  

  • 11. A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma.
    D'Avola D; Lñarrairaegui M; Bilbao JI; Martinez-Cuesta A; Alegre F; Herrero JI; Quiroga J; Prieto J; Sangro B
    Hepatogastroenterology; 2009; 56(96):1683-8. PubMed ID: 20214218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of a Scout Dose Preceding Hepatic Radioembolization with 166Ho Microspheres.
    Prince JF; van Rooij R; Bol GH; de Jong HW; van den Bosch MA; Lam MG
    J Nucl Med; 2015 Jun; 56(6):817-23. PubMed ID: 25931477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
    Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
    J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of primary and secondary hepatic malignancies associated with hepatopulmonary shunting.
    Gaba RC; Zivin SP; Dikopf MS; Parvinian A; Casadaban LC; Lu Y; Bui JT
    Radiology; 2014 May; 271(2):602-12. PubMed ID: 24533871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of C-arm CT acquired parenchymal blood volume (PBV) with 99mTc-macroaggregated albumin (MAA) SPECT/CT for radioembolization work-up.
    Weissinger M; Vogel J; Kupferschläger J; Dittmann H; Castaneda Vega SG; Grosse U; Artzner C; Nikolaou K; la Fougere C; Grözinger G
    PLoS One; 2020; 15(12):e0244235. PubMed ID: 33378338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: a single centre experience of 45 consecutive patients.
    Saxena A; Meteling B; Kapoor J; Golani S; Danta M; Morris DL; Bester L
    Int J Surg; 2014 Dec; 12(12):1403-8. PubMed ID: 25091398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoembolic hepatopulmonary shunt reduction to allow safe yttrium-90 radioembolization lobectomy of hepatocellular carcinoma.
    Gaba RC; Vanmiddlesworth KA
    Cardiovasc Intervent Radiol; 2012 Dec; 35(6):1505-11. PubMed ID: 22526098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma.
    Lance C; McLennan G; Obuchowski N; Cheah G; Levitin A; Sands M; Spain J; Srinivas S; Shrikanthan S; Aucejo FN; Kim R; Menon KV
    J Vasc Interv Radiol; 2011 Dec; 22(12):1697-705. PubMed ID: 21983055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioembolization With Yttrium-90 Resin Microspheres in Hepatocellular Carcinoma: A Multicenter Prospective Study.
    Kim DY; Park BJ; Kim YH; Han KH; Cho SB; Cho KR; Uhm SH; Choe JG; Choi JY; Chun HJ; Lee HC; Gwon DI; Lee KH; Yoon JH; Chung JW; Kim CW; Heo J; Kim JK; Joo YE
    Am J Clin Oncol; 2015 Oct; 38(5):495-501. PubMed ID: 24064753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indicators of Lung Shunt Fraction Determined by Technetium-99 m Macroaggregated Albumin in Patients with Hepatocellular Carcinoma.
    Kallini JR; Gabr A; Hickey R; Kulik L; Desai K; Yang Y; Gates VL; Riaz A; Salem R; Lewandowski RJ
    Cardiovasc Intervent Radiol; 2017 Aug; 40(8):1213-1222. PubMed ID: 28280976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.